# Validus Pharmaceuticals

Validus Pharmaceuticals is an Asset Manager based in Parsippany, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Parsippany, United States
- **Region:** North America
- **Address:** 90 East Halsey Road, Suite 210, Parsippany, NJ 07054
- **Assets under management:** Undisclosed
- **Website:** validuspharma.com
- **LinkedIn:** https://www.linkedin.com/company/validus-pharmaceuticals

## Regulatory record

- **Reports private funds:** No

## About

Validus is focused on acquiring, reformulating, and marketing prescription products in specialty therapeutic areas. Our business is based on acquisition of established products that are FDA-approved and satisfy unmet clinical needs.

## Sectors

- Healthcare Services

## People

- Emile Williams — Chief Operating Officer

## Questions

### Who runs investment and operational decisions at Validus Pharmaceuticals?

Emile Williams is the Chief Operating Officer, according to the firm's website, and oversees commercial and operational strategy. He previously served as EVP and Chief Commercial Officer at Shionogi, and held senior finance roles at Novartis and Hoffmann-La Roche. No additional principals or investment committee members are publicly disclosed.

### How does Validus source its product pipeline?

Validus acquires existing FDA-approved prescription products rather than conducting primary clinical development. The firm then reformulates these assets to address specific unmet needs, a model that relies on its ability to identify approved molecules with persistent demand and navigate regulatory pathways for line extensions or reformulations.

### What therapeutic areas does Validus target?

The firm's public materials reference specialty therapeutic areas with unmet clinical needs, including central nervous system, women's health, and cardiovascular conditions. It does not disclose a list of excluded sectors but operates entirely within FDA-approved prescription medicine categories.

### Which products or deals has Validus completed?

Validus does not publicly name specific acquired products or transaction values. The firm states its portfolio is built on established FDA-approved medicines, but no individual deal announcements, seller names, or product brands appear in its current public disclosures.

## Related profiles

- [Keystone Capital Private Equity](https://altss.com/profile/keystone-capital-private-equity-shanghai)
- [Lancet Capital](https://altss.com/profile/lancet-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/validus-pharmaceuticals

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology